Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“PATINA trial finally cracks HR+ HER2+ mBC maintenance
After induction chemo, adding a CDK4/6 inhibitor works.
PATINA, Phase III, n=518
HR+ HER2+ metastatic breast cancer
No progression after 4–8 cycles of taxane + anti-HER2 induction
Maintenance arms (1:1)
Anti-HER2 + endocrine + palbociclib
Anti-HER2 + endocrine alone
Primary endpoint – PFS
44.3 vs 29.1 months
HR 0.75 (95% CI 0.59–0.96)
+15.2 months absolute gain
Trade-off
More neutropenia, but febrile neutropenia <1% No treatment-related deaths
Bottom line Adding
CDK4/6 inhibition to anti-HER2 + endocrine therapy meaningfully prolongs maintenance PFS.”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence A. Francis, Filipa Lynce, Jane Lanzillotti, Carter DuFrane, Anna Wall, Carrie Strand, Ian Krop, Ines Vaz-Luis, Debu Tripathy, Sherene Loi, Aleix Prat, Matthew Goetz, Santiago Escrivá-de-Romaní, David Porter, Jennifer Spoenlein, Daniel G. Stover, Sagar Sardesai, Pierre Heudel, Maria Koehler, Cynthia Huang Bartlett, Ariadna Holynskyj, Prashanth Gopalakrishna, Eric Gauthier, Pharm.D., Suzette Delaloge, Kathy Miller., Eric P. Winer, Luca Gianni, Ann H. Partridge, Angela DeMichele, and Lisa A. Carey
More posts featuring Rishabh Jain
